Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895442 | 0.93 | HIF1A (0.44) | HIF1AS1PR1MAOBHPGDPPARG | |
| SCHEMBL9895438 | 0.93 | HIF1A (0.44) | HIF1AS1PR1MAOBHPGDPPARG | |
| SCHEMBL9895316 | 0.91 | HIF1A (0.49) | HIF1AS1PR1MAOBHPGDL3MBTL1 | |
| SCHEMBL9894514 | 0.89 | HIF1A (0.48) | HIF1AMAOBPPARGPPARAL3MBTL1 | |
| SCHEMBL9894986 | 0.87 | HIF1A (0.46) | HIF1APPARGPPARAL3MBTL1ALDH1A1 | |
| SCHEMBL9895311 | 0.84 | HIF1A (0.48) | HIF1AS1PR1MAOBHPGDL3MBTL1 | |
| SCHEMBL9895318 | 0.84 | HIF1A (0.48) | HIF1AS1PR1MAOBHPGDL3MBTL1 | |
| SCHEMBL9895313 | 0.84 | HIF1A (0.48) | HIF1AS1PR1MAOBHPGDL3MBTL1 | |
| SCHEMBL9894795 | 0.83 | HRH3 (0.45) | HIF1AKDM4EALDH1A1 | |
| SCHEMBL9894515 | 0.82 | HIF1A (0.46) | HIF1AMAOBPPARGPPARAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | claimed |
| EP-2565180-A2 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oscotec Inc. (KR) | 2013-03-06 | — | — | EP | claimed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | claimed |
| US-8772290-B2 | Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same | Oscotech Inc. (KR) | 2014-07-08 | — | — | US | disclosed |
| EP-2565180-A2 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oscotec Inc. (KR) | 2013-03-06 | — | — | EP | disclosed |
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | OSCOTEC INC. (KR) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149707-A1 | ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HIF1A, HIF1AN, EGLN3 | HIF1A 1/4885S1PR1 1723/4885MAOB 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.